THE JOURNAL OF FAMILY PRACTICE

Management of rheumatoid arthritis

POSTTEST

Credit will be awarded upon successful completion of assessment questions (70% or better) and completion of program evaluation.

RELEASE DATE: *October 1, 2007* EXPIRATION DATE: *September 30, 2008*

Please circle correct answer for each question

1. **Arthritis and other rheumatic conditions are the leading cause of disability in the US.**
   a. True b. False

2. **Initial referral to a rheumatologist is advised if the patient has:**
   a. ≥3 swollen joints
   b. Positive squeeze test across metacarpophalangeal/metatarsophalangeal joints
   c. Morning stiffness for ≥30 minutes
   d. All of the above

3. **Which of the following have been suggested as risk factors for rheumatoid arthritis (RA)?**
   a. Viral pathogens
   b. Smoking
   c. Alcohol
   d. All of the above
   e. a and b

4. **The squeeze test is used to:**
   a. Detect tenderness in the patient's small peripheral joints
   b. Determine strength in the small peripheral joints
   c. Detect social phobias
   d. Detect tenderness in the elbows and knees

5. **Blood tests for RA should include:**
   a. Rheumatoid factor (RF)
   b. Erythrocyte sedimentation rate
   c. C-reactive protein
   d. All of the above

6. **Compared with RF, anti-cyclic citrullinated peptide antibody testing is:**
   a. More sensitive and less specific for RA
   b. Less sensitive and less specific for RA
   c. Less sensitive and more specific for RA
   d. More sensitive and more specific for RA

7. **Before a patient is prescribed disease-modifying antirheumatic drugs (DMARDs) by a rheumatologist, they may be prescribed:**
   a. Nonsteroidal anti-inflammatory drugs
   b. Antibiotics
   c. Glucocorticoids
   d. All of the above
   e. Both a and c

8. **Which of the following DMARDs is usually the drug of first choice during treatment of RA?**
   a. Methotrexate
   b. Leflunomide
   c. Infliximab
   d. Anakinra

9. **Which of the following DMARDs is an anti-tumor necrosis factor agent?**
   a. Adalimumab
   b. Etanercept
   c. Infliximab
   d. All of the above

10. **Long-term management of RA includes continued monitoring for:**
    a. Infection
    b. GI bleeding
    c. Lymphoproliferative disease
    d. CVD
    e. All of the above

PROGRAM EVALUATION

Please complete the evaluation

Have objectives for the activity been met?

Identify and address barriers to diagnosis and improved outcomes for RA in the primary care setting
Yes ☐ No ☐

Demonstrate the importance of an early and accurate diagnosis of RA
Yes ☐ No ☐

Examine appropriate RA patient management through a collaborative team approach
Yes ☐ No ☐

Describe the monitoring of potential adverse events and benefits of primary care management or RA patients
Yes ☐ No ☐

Was this publication fair, balanced, and free of commercial bias?
Yes ☐ No ☐

CERTIFICATE REQUEST

Please print clearly

I certify that I have completed this educational activity and posttest and claim 1.5 credits.

SIGNATURE

CME CREDIT ____ CE CREDIT ____

FIRST NAME, MI

LAST NAME

DEGREE TITLE

AFFILIATION

SPECIALTY

MAILING ADDRESS

CITY STATE ZIP

DAYTIME TELEPHONE

FAX

E-MAIL

To receive credit, please complete the posttest and evaluation form, and mail to:

The Chatham Institute
26 Main Street, Suite #350
Program T7V33MG
Chatham, NJ 07928

Or fax to: **800-239-2984**

Please allow 8 weeks for processing.